Subconjunctival injection of triamcinolone in the treatment of lid retraction of patients with thyroid eye disease: a case series

被引:36
|
作者
Chee, E. [1 ]
Chee, S-P [1 ,2 ,3 ]
机构
[1] Natl Univ Singapore, Yong Loo Lin Sch Med, Singapore Natl Eye Ctr, Singapore 117548, Singapore
[2] Natl Univ Singapore, Yong Loo Lin Sch Med, Singapore Eye Res Inst, Singapore 117548, Singapore
[3] Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Ophthalmol, Singapore 117548, Singapore
关键词
subconjunctival; triamcinolone injection; lid retraction; thyroid eye disease;
D O I
10.1038/sj.eye.6702933
中图分类号
R77 [眼科学];
学科分类号
100212 ;
摘要
Purpose To report the results of subconjunctival injection of triamcinolone in the treatment of thyroid eye disease-related lid retraction. Intervention Patients with either unilateral or bilateral upper lid retraction, secondary to thyroid eye disease, diagnosed during the period of February 2004 to June 2005 were recruited. An injection of 0.5 ml of triamcinolone acetonide (40 mg/ml kenalog) with 0.1 ml of 2% lignocaine was injected into the subconjunctival region of the lid between the conjunctiva and Muller's muscle under topical anaesthesia on upper lid eversion. Pre- and post-procedure measurements included lid aperture, marginal reflex distance, the amount of lagophthalmos, and intraocular pressure measurements. Photographs were also obtained before the procedure and at subsequent visits. Follow-up was done at 2 weeks, 1, 3, 6 months and at 1 year. Results Three of the four patients had resolution of their upper lid retraction within 1 month of treatment, with one patient requiring a repeat triamcinolone injection. The patient who had fibrotic muscles did not respond to triamcinolone injections and required surgical correction. Conclusion Upper lid subconjunctival triamcinolone appears to be an effective treatment option in reducing lid retraction in patients with recent onset of thyroid eye disease.
引用
收藏
页码:311 / 315
页数:5
相关论文
共 50 条
  • [31] Thyroid Eye Disease: Pathogenesis and Treatment
    Sikder, Shameema
    Weinberg, Robert S.
    OPHTHALMOLOGICA, 2010, 224 (04) : 199 - 203
  • [32] Teprotumumab for the treatment of thyroid eye disease
    Ju, Yongjing
    Yang, Junyi
    EXPERT REVIEW OF CLINICAL IMMUNOLOGY, 2020, 16 (08) : 739 - 743
  • [33] Treatment Options for Thyroid Eye Disease
    Pillar, Angelique J.
    Richa, D. Chimene
    CURRENT TREATMENT OPTIONS IN NEUROLOGY, 2014, 16 (08)
  • [34] Correction of lower eyelid retraction combined with entropion in thyroid eye disease patients of East Asian ancestry
    Ma, Yue
    Tang, Meiting
    Kikkawa, Don O.
    Lu, Wei
    EUROPEAN JOURNAL OF OPHTHALMOLOGY, 2022, 32 (04) : 2475 - 2480
  • [35] Rituximab in the Treatment of Thyroid Eye Disease: A Review
    Ostrowski, Rochella A.
    Bussey, Melissa R.
    Shayesteh, Yasmin
    Jay, Walter M.
    NEURO-OPHTHALMOLOGY, 2015, 39 (03) : 109 - 115
  • [36] Medical and surgical treatment of thyroid eye disease
    Hall, Anthony J. H.
    Topliss, Duncan J.
    INTERNAL MEDICINE JOURNAL, 2022, 52 (01) : 14 - 20
  • [37] Tumors Masquerading in Patients with Thyroid Eye Disease
    Griepentrog, Gregory J.
    Burkat, Cat N.
    Kikkawa, Don O.
    Lucarelli, Mark J.
    ORBIT-THE INTERNATIONAL JOURNAL ON ORBITAL DISORDERS-OCULOPLASTIC AND LACRIMAL SURGERY, 2013, 32 (04): : 260 - 262
  • [38] How patients experience thyroid eye disease
    Smith, Terry J.
    Hegedus, Laszlo
    Lesser, Ira
    Perros, Petros
    Dorris, Kimberly
    Kinrade, Michele
    Troy-Ott, Patti
    Wuerth, Laura
    Nori, Mukund
    FRONTIERS IN ENDOCRINOLOGY, 2023, 14
  • [39] Treatment of Hyperthyroidism in Graves' Disease Complicated by Thyroid Eye Disease
    Bartalena, Luigi
    Smith, Terry J.
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2025, 110 (04) : 922 - 930
  • [40] A curative effect evaluation of intensity-modulated radiation therapy combined with periorbital triamcinolone acetonide injection in treating thyroid eye disease patients with active extraocular muscle but low CAS
    Zhang, Hao
    He, Weimin
    SCIENTIFIC REPORTS, 2025, 15 (01):